Journal article

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study

David M Hyams, Arlene Chan, Celia de Oliveira, Raymond Snyder, Jeferson Vinholes, M William Audeh, Victor M Alencar, Janine Lombard, Bijoyesh Mookerjee, John Xu, Kathryn Brown, Paula Klein



Hormone receptor-positive breast cancer is treated with estrogen inhibitors. Fulvestrant (FASLODEX™), an estrogen receptor (ER) antagonist with no known agonist effects, competitively binds, blocks and degrades the ER. Vascular endothelial growth factor (VEGF) may mediate resistance to ER antagonists. Cediranib is a highly potent VEGF signaling inhibitor with activity against all three VEGF receptors. This randomized Phase II study evaluated cediranib plus fulvestrant. Postmenopausal women with hormone-sensitive metastatic breast cancer were eligible. The primary endpoint was progression-free survival (PFS). Secondary endpoints included objective response rate (ORR), duration of response, cl..

View full abstract

University of Melbourne Researchers